scholarly journals Massive Pulmonary Embolism Causing Cardiac Arrest Managed with Systemic Thrombolytic Therapy: A Case Report

2021 ◽  
Vol 22 ◽  
Author(s):  
Stephanie R. Welle ◽  
Michael F. Harrison
Keyword(s):  
Pulmonary Embolism ◽  
Cardiac Arrest ◽  
Case Report ◽  
Thrombolytic Therapy ◽  
Massive Pulmonary Embolism ◽  
Systemic Thrombolytic Therapy

Clot Extraction With the FlowTriever Device in Acute Massive Pulmonary Embolism

2016 ◽  
Vol 31 (10) ◽  
pp. 676-679 ◽  
Author(s):  
Aaron Samuel Weinberg ◽  
Suhail Dohad ◽  
Danny Ramzy ◽  
Hooman Madyoon ◽  
Victor F. Tapson
Keyword(s):  
Pulmonary Embolism ◽  
Case Report ◽  
Thrombolytic Therapy ◽  
Clinical Guidelines ◽  
Treatment Options ◽  
Massive Pulmonary Embolism ◽  
Novel Device ◽  
First Case ◽  
Systemic Thrombolytic Therapy ◽  
Acute Pe

Clinical guidelines support the use of systemic thrombolytic therapy for acute massive pulmonary embolism (PE). When anticoagulation and thrombolysis fail or are contraindicated, options become limited. We report an acute PE case in which treatment options were limited, and a novel device, the FlowTriever (Inari Medical, Irvine, California), was successfully used. This is the first case report of the use of this device that we are aware of.

Massive pulmonary embolism in a young boy with T-cell leukaemia

2014 ◽  
Vol 34 (03) ◽  
pp. 233-236
Author(s):  
C. Martin ◽  
F. Alt ◽  
A. Wingerter ◽  
G. Staatz ◽  
H. Schinzel ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Acute Pulmonary Embolism ◽  
Recombinant Tissue Plasminogen Activator ◽  
Massive Pulmonary Embolism ◽  
Bleeding Complications ◽  
Cell Leukaemia ◽  
Malignant Diseases ◽  
Systemic Thrombolytic Therapy ◽  
Tissue Plasminogen

SummaryAcute pulmonary embolism (PE) is a serious complication in association with malignant diseases. We describe the successful treatment of PE applying a systemic thrombolytic therapy in a 4-year-old boy with acute lymphoblastic leukaemia.The thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) 0.1 mg/ kg bodyweight per hour for six hours was continued for six days without important side effects. In particular no bleeding complications were observed. Computed tomography with contrast revealed a remarkable regression of the central PE. Without further delays the chemotherapy was resumed.

Role of rheolytic thrombectomy in massive pulmonary embolism with contraindication to systemic thrombolytic therapy

2010 ◽  
Vol 5 (6) ◽  
pp. 716-721 ◽  
Author(s):  
Dabit Arzamendi ◽  
Luc Bilodeau ◽  
Reda Ibrahim ◽  
Stephane Noble ◽  
Richard Gallo ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Thrombolytic Therapy ◽  
Massive Pulmonary Embolism ◽  
Systemic Thrombolytic Therapy ◽  
Rheolytic Thrombectomy
Sign in / Sign up

Export Citation Format

Share Document